A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s
Objective: To select up to 40 delivery sites to successfully recruit and retain a participant population representative of people with Parkinson’s disease (PwP) in the…Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease
Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study
Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension
Objective: To determine the effect of different classes of antihypertensive medications on Parkinson’s disease progression. Background: Cardiovascular risk factors such as hypertension can worsen Parkinson’s…Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the effects of transcutaneous vagus nerve stimulation (tVNS) on gait, motor function, and freezing of gait (FOG) in patients with Parkinson’s disease…Updated Meta-analysis Assessing GLP-1 Agonists for Parkinson’s Disease
Objective: Evaluate the efficacy and safety of Glucagon-like peptide-1 (GLP-1) agonists on Parkinson’s disease (PD). Background: The idea of repositioning drugs used to treat PD…Serum based estimations of CFAH, Gelsolin, CNDP1 and DKK3 levels suggest involvement of multiple pathways in pathogenesis of Parkinson’s disease.
Objective: To estimate levels of complement factor H (CFAH), phosphorylated alpha-syn (p- a-syn), gelsolin, carnosine dipeptidase-1 (CNDP1) and DKK3 in serum of Parkinson’s disease (PD) patients…Basal Ganglia Physiomarkers of Non-motor Symptoms in Parkinson’s Disease: a Systematic Review
Objective: To systematically review the evidence linking basal ganglia local field potentials to non-motor symptoms in Parkinson’s disease. Background: Deep brain stimulation for Parkinson’s disease…Quantitative Measures of Cutaneous Phosphorylated Alpha-Synuclein: Powering a Disease Modification Clinical Trial In Parkinson’s Disease
Objective: To use a novel quantitative assessment of cutaneous P-SYN in a pilot study of patients with Parkinson’s disease (PD) and healthy volunteers (HVs) to…
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 436
- Next Page »